Nasdaq grts.

0.084%. Get the latest GRTS (GRTS) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment …WebGritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.A. Gritstone Bio ( GRTS) does not have any upcoming earnings reports scheduled yet. The last reported earnings were for reported on November 8, 2023 for Q3 and the Actual Revenue was $1.6M, which ...Nov 21, 2023 · Eric Enderson. November 21, 2023. In the last trading session, 1.28 million Gritstone Bio Inc (NASDAQ:GRTS) shares changed hands as the company’s beta touched 0.47. With the company’s per share price at $1.32 changed hands at -$0.04 or -2.94% during last session, the market valuation stood at $125.85M. GRTS’s last price was a discount ... Nov 8, 2021 · Gritstone bio's $785 million collaboration for HIV therapies has quantified the value of EDGE more than any Wall Street analyst could ever do. Gilead has already given GRTS $30 million upfront and ...

Eric Enderson. November 21, 2023. In the last trading session, 1.28 million Gritstone Bio Inc (NASDAQ:GRTS) shares changed hands as the company’s beta touched 0.47. With the company’s per share price at $1.32 changed hands at -$0.04 or -2.94% during last session, the market valuation stood at $125.85M. GRTS’s last price was a discount ...Gritstone Bio Inc (NASDAQ:GRTS) trade information. Upright in the red during last session for losing -4.86%, in the last five days GRTS remained trading in the red while hitting it’s week-highest on Friday, 11/10/23 when the stock touched $1.37 price level, adding 14.27% to its value on the day.Aug 10, 2022 · Celebrations may be in order for Gritstone bio, Inc. (NASDAQ:GRTS) shareholders, with the analysts delivering a significant upgrade to their statutory estimates for the company. The analysts have ...

EMERYVILLE, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today ...

Verizon, Walgreens, and 4 Other Stocks. The S&P 500's Best Payouts: 7%+ Dividend Yields. Get the latest GRTS (GRTS) real-time quote, historical performance, charts, and other financial...Gritstone bio, Inc. Common Stock (GRTS) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets.WebNov 24, 2023 · Gritstone bio (GRTS) Stock Price, News & Analysis $1.37 -0.01 (-0.72%) (As of 11/14/2023 ET) Compare Today's Range $1.36 $1.49 50-Day Range $1.19 $2.85 52-Week Range $1.14 $4.05 Volume 1.57 million shs Average Volume 1.17 million shs Market Capitalization $130.62 million P/E Ratio N/A Dividend Yield N/A Price Target $7.33 Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.

GRTS Earnings Date and Information. Gritstone bio last posted its earnings data on November 8th, 2023. The reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.02. The firm earned $1.57 million during the quarter, compared to analysts' expectations of $2.10 million.

Nov 27, 2023 · The latest price target for Gritstone Bio ( NASDAQ: GRTS) was reported by Piper Sandler on Thursday, September 28, 2023. The analyst firm set a price target for 7.00 expecting GRTS to rise to ...

clinical-stage biotechnology company, which engages in developing the next generation of cancer immunotherapies to fight multiple cancer types. The company was ...ปิด: 1 ธ.ค., 17 นาฬิกา 27 นาที 54 วินาที GMT-5 · USD · NASDAQ · ข้อจำกัดความรับผิด ... GRTS. $1.53. GRTS 17.69%. insightsกิจกรรมสำคัญ. กิจกรรมสำคัญจะแสดงบทความข่าว ...TipRanks | Stock Market Research, News and Analyst Forecasts - TipRanks.comGritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of cancer immunotherapies to fight multiple cancer types.Mar 8, 2022 · Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. Gritstone bio, Inc. (NASDAQ:GRTS) announced its quarterly earnings results on Wednesday, November, 8th. The company reported ($0.33) earnings per …Web

Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.Maybe you’ve never invested before. Maybe you have no clue what the difference is between NASDAQ and the New York Stock Exchange. Regardless, the name Charles Schwab probably rings a bell.Insiders seem to have made the most of their holdings by selling US$221k worth of Gritstone bio, Inc. (NASDAQ:GRTS) stock at an average sell price of US$22.10 during the past year. The company's ...Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.The following insider purchased GRTS shares in the last 24 months: Vassiliki Economides ($22,800.00). How much insider buying is happening at Gritstone bio? Insiders have purchased a total of 12,000 GRTS shares in the last 24 months for a total of $22,800.00 bought.

Today’s penny stock pick is the clinical-stage biotechnology company, Gritstone bio, Inc. (NASDAQ: GRTS). Gritstone bio, Inc. engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, a neoantigen-based immunotherapy, which is in Phase …

EMERYVILLE, Calif., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today ...Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.Find the latest news headlines from Gritstone bio, Inc. Common Stock (GRTS) at Nasdaq.com.Gritstone bio ( NASDAQ: GRTS) is developing a second-generation covid vaccine that is designed to work in two ways; first, it will generate a robust neutralizing antibodies response, and second ...Gritstone bio, Inc. Common Stock (GRTS) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. The average price predicted for Gritstone Bio Inc (GRTS) by analysts is $10.40, which is $9.08 above the current market price. The public float for GRTS is 87.55M, and at present, short sellers hold a 9.62% of that float. On November 30, 2023, the average trading volume of GRTS was 2.33M shares. The electric vehicle boom is accelerating – and ...Gritstone Bio Inc (NASDAQ: GRTS)’s stock price has plunge by -7.69relation to previous closing price of 1.69. Nevertheless, the company has seen a -14.75% plunge in its stock price over the last five trading sessions. Zacks Investment Research reported 2023-10-16 that Gritstone bio Inc. (GRTS)Gracell Biotechnologies Inc. (NASDAQ:GRCL), Blue Ridge Bankshares, Inc. (NYSE:BRBS), Gritstone bio, Inc. (NASDAQ:GRTS), and Ebix, Inc. (NASDAQ:EBIX) are some best stocks for day trading. Click ...

Gritstone Bio Inc (NASDAQ: GRTS)’s stock price has soared by 17.69 in relation to previous closing price of 1.30. Nevertheless, the company has seen a gain of 11.68% in its stock price over the last five trading days. Zacks Investment Research reported 2023-10-16 that Gritstone bio Inc. (GRTS) has been upgraded to a Zacks Rank #2 (Buy ...

EMERYVILLE, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today ...

GRTS Latest Real Time Trades. Select time range to see more trades: Last 100 Trades. NLS Time (ET) NLS Price. NLS Share Volume. 16:00:04. $ 2.64. 861.WebJun 3, 2021 · The Last 12 Months Of Insider Transactions At Gritstone bio. The Executive VP & CTO, Roman Yelensky, made the biggest insider sale in the last 12 months. That single transaction was for US$221k ... A. Gritstone Bio ( GRTS) does not have any upcoming earnings reports scheduled yet. The last reported earnings were for reported on November 8, 2023 for Q3 and the Actual Revenue was $1.6M, which ...A. Gritstone Bio ( GRTS) does not have any upcoming earnings reports scheduled yet. The last reported earnings were for reported on November 8, 2023 for Q3 and the Actual Revenue was $1.6M, which ...Find the latest Insider Activity data for Gritstone bio, Inc. Common Stock (GRTS) at Nasdaq.com. EMERYVILLE, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced... -- 10,000 participant randomized Phase 2b study will evaluate Gritstone s self-amplifying mRNA (samRNA) vaccine candidate containing Spike plus ...EMERYVILLE, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today ...Gritstone bio ( NASDAQ: GRTS) is developing a second-generation covid vaccine that is designed to work in two ways; first, it will generate a robust neutralizing antibodies response, and second ...Follow. EMERYVILLE, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines ...MT. B. Riley Initiates Coverage of Gritstone bio With Buy Rating, Price Target of $8 Per Share. Mar. 28. MT. HC Wainwright Adjusts Gritstone bio's Price Target to $7 From $12, Keeps Buy Rating. Nov. 07. MT. Piper Sandler Starts Gritstone bio at Overweight With $6 Price Target.

Dec 23, 2020 · Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of cancer immunotherapies to fight multiple cancer types. Gritstone develops its ... 20 ม.ค. 2564 ... (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, and ...About Gritstone bio Gritstone bio, Inc. (Nasdaq: GRTS) is a clinical-stage biotechnology company that aims to create the world’s most potent vaccines. We leverage our innovative vectors and ...In the last trading session, 1.12 million Gritstone Bio Inc (NASDAQ:GRTS) shares changed hands as the company’s beta touched 0.61. With the company’s per share price at $1.89 changed hands at -$0.06 or -3.08% during last session, the market valuation stood at $175.92M. GRTS’s last price was a discount, traded about -114.29% off its 52 ...Instagram:https://instagram. westwood holdingsdocusign stockskennedy silver dollar worthnanoxplore stock Find the latest Institutional Holdings data for Gritstone bio, Inc. Common Stock (GRTS) at Nasdaq.com. Nov 27, 2023 · GRTS is trading at a 62% discount. Price $1.37. Nov 27, 2023. Fair Value $5.77. Nov 27, 2023 ... Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) thematic fundsbest dental insurance plans in nc Here's Why We're Not Too Worried About Gritstone bio's (NASDAQ:GRTS) Cash Burn Situation May 26. Consensus revenue estimates increase to US$46.1m May 13. First quarter 2021 earnings released: EPS US$0.10 (vs US$0.71 loss in 1Q 2020) May 07. Gritstone Oncology EPS beats by $0.41, beats on revenueEMERYVILLE, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today ... uber earnings statement Find the latest Institutional Holdings data for Gritstone bio, Inc. Common Stock (GRTS) at Nasdaq.com.EMERYVILLE, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today ...